Li Junrui, Fu Yingju, Zhao Baochun, Xiao Ying, Chen Ruiying
Department of Infectious Disease, Tangshan Worker's Hospital, No. 27 Wenhua Road, Tangshan, Hebei, 063000, China,
Tumour Biol. 2014 Jan;35(1):821-9. doi: 10.1007/s13277-013-1113-4. Epub 2013 Aug 25.
Myeloperoxidase (MPO) is a phase I enzyme playing a crucial role in metabolically activating a wide range of procarcinogens, such as polycyclic aromatic hydrocarbons and aromatic amines. The G463A polymorphism in the promoter region of the MPO gene has been indicated in lung cancer risk. To investigate the precise association of MPO G463A polymorphism with the lung cancer risk, we performed this comprehensive meta-analysis with large available data published to date. The included 24 individual studies involving a total of 8,313 cases and 8,728 controls were identified by searching the PubMed, Embase, and Wanfang databases. The crude odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated to estimate the association. Stratified analyses by ethnicity, source of controls, smoking status, and histological types were also conducted. Overall, the MPO G463A polymorphism was negatively related to the development of lung cancer in the following genetic models (A vs. G, OR = 0.90, 95% CI = 0.82-0.99, P OR = 0.029; GA vs. GG, OR = 0.89, 95% CI = 0.80-0.98, P OR = 0.022; AA + GA vs. GG, OR = 0.89, 95% CI = 0.81-0.98, P OR = 0.023). Stratified analyses by ethnicity indicated that the variant genotype of MPO G463A was associated with a decreased risk of lung cancer in Asians and Caucasians. Similar findings were observed among the smokers and population-based case-control studies. The MPO G463A polymorphism seemed to exert no effect on lung adenocarcinoma and squamous cell carcinoma. The comprehensive meta-analysis shows that the polymorphism of MPO G463A is a protective factor for lung cancer, particularly among the populations of Asians, Caucasians, and smokers.
髓过氧化物酶（MPO）是一种I相酶，在多种前致癌物（如多环芳烃和芳香胺）的代谢激活过程中发挥关键作用。MPO基因启动子区域的G463A多态性与肺癌风险有关。为了研究MPO G463A多态性与肺癌风险的确切关联，我们利用迄今已发表的大量可用数据进行了这项全面的荟萃分析。通过检索PubMed、Embase和万方数据库，确定了24项个体研究，共涉及8313例病例和8728例对照。计算了粗比值比（OR）和相应的95%置信区间（CI）以评估关联。还按种族、对照来源、吸烟状况和组织学类型进行了分层分析。总体而言，在以下遗传模型中，MPO G463A多态性与肺癌的发生呈负相关（A vs. G，OR = 0.90，95% CI = 0.82 - 0.99，P OR = 0.029；GA vs. GG，OR = 0.89，95% CI = 0.80 - 0.98，P OR = 0.022；AA + GA vs. GG，OR = 0.89，95% CI = 0.81 - 0.98，P OR = 0.023）。按种族进行的分层分析表明，MPO G463A的变异基因型与亚洲人和高加索人患肺癌风险的降低有关。在吸烟者和基于人群的病例对照研究中也观察到了类似的结果。MPO G463A多态性似乎对肺腺癌和鳞状细胞癌没有影响。这项全面的荟萃分析表明，MPO G463A多态性是肺癌的一个保护因素，特别是在亚洲人、高加索人和吸烟者群体中。
